|
1-Piperidinamine, N-hydroxy-N-nitroso-
|
|
56329-24-9
|
|
Ozoralizumab
|
奥利组单抗
|
1167985-17-2
|
|
Blosozumab
|
布索组单抗
|
1132758-87-2
|
|
Sirukumab
|
西鲁库单抗
|
1194585-53-9
|
|
Enoticumab
|
依诺苏单抗
|
1192578-27-0
|
|
Vandortuzumab Vedotin
|
维汀-万多妥珠单抗
|
1471985-92-8
|
|
Afasevikumab
|
阿法库单抗
|
1589503-30-9
|
|
Amivantamab
|
埃万妥单抗
|
2171511-58-1
|
|
JQKD-82
|
|
2410512-38-6
|
|
ML339
|
|
2579689-83-9
|
|
INE963
|
|
2640567-43-5
|
|
OTX 008
|
|
286936-40-1
|
|
Enoblituzumab
|
依诺妥珠单抗
|
1353485-38-7
|
|
SBI-425
|
|
1451272-71-1
|
|
2,4-Dichlorophenoxyacetyl chloride
|
2,4-二氯苯氧乙酰氯
|
774-74-3
|
|
Mc-Val-Ala-PAB-PNP
|
|
1639939-40-4
|
|
Tregalizumab
|
曲利组单抗
|
1207446-68-1
|
|
Flanvotumab
|
法兰妥单抗
|
1188277-05-5
|
|
Clazakizumab
|
克拉扎珠单抗
|
1236278-28-6
|
|
Tafasitamab
|
|
1422527-84-1
|
|
AZD-1940
|
|
881413-29-2
|
|
Bocidelpar
|
|
2095128-20-2
|
|
NCC007
|
|
2342583-66-6
|
|
Lirilumab
|
利瑞鲁单抗
|
1000676-41-4
|
|
Sigma-1 receptor antagonist 2
|
|
1639220-15-7
|
|
Onartuzumab
|
奥那妥组单抗
|
1133766-06-9
|
|
Indatuximab Ravtansine
|
雷英妥昔单抗
|
1238517-16-2
|
|
Quilizumab
|
奎利珠单抗
|
1228538-47-3
|
|
Tesidolumab
|
特度鲁单抗
|
1531594-08-7
|
|
Rovalpituzumab
|
洛伐妥珠单抗
|
1613313-01-1
|
|
Xentuzumab
|
珍妥珠单抗
|
1417158-65-6
|
|
AZ32
|
|
2288709-96-4
|
|
JYN42346
|
|
1903742-34-6
|
|
TH5427
|
|
2253744-56-6
|
|
MRTX1719
|
|
2630904-45-7
|
|
Zunsemetinib
|
|
1640282-42-3
|
|
1-((2R,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)-5-(trifluoromethyl)pyrimidine-2,4(1H,3H)-dione
|
|
1380532-27-3
|
|
Crenezumab
|
克瑞组单抗
|
1095207-05-8
|
|
Tabalumab
|
他贝芦单抗
|
1143503-67-6
|
|
Fasinumab
|
法司努单抗
|
1190239-42-9
|
|
Lacutamab
|
拉可妥单抗
|
2187368-16-5
|
|
Indusatumab Vedotin
|
|
1514889-12-3
|
|
Tisotumab
|
替索妥单抗
|
1418628-81-5
|
|
Olendalizumab
|
奥仑达利珠单抗
|
1337966-73-0
|
|
NCGC00378430
|
|
920650-00-6
|
|
Apostatin-1
|
|
2559703-06-7
|
|
Ublituximab
|
乌妥昔单抗
|
1174014-05-1
|
|
Narnatumab
|
那呐妥单抗
|
1188275-92-4
|
|
Demcizumab
|
登赛珠单抗
|
1243262-17-0
|
|
Imgatuzumab
|
伊马曲单抗
|
959963-46-3
|
|
Lokivetmab
|
洛吉维单抗
|
1533403-95-0
|
|
Rinucumab
|
利努苏单抗
|
1569263-06-4
|
|
Tilavonemab
|
替拉奈单抗
|
2096513-89-0
|
|
GI 181771
|
|
305366-98-7
|
|
Ponezumab
|
泊奈组单抗
|
1178862-65-1
|
|
Caplacizumab
|
卡拉西单抗
|
915810-67-2
|
|
Actoxumab
|
阿克托舒单抗
|
1245634-25-6
|
|
Refanezumab
|
瑞法奈珠单抗
|
1233953-61-1
|
|
SUC-ALA-ALA-PRO-PHE-PNA
|
|
107409-54-1
|
|
Ro60-0175
|
|
169675-08-5
|
|
AMG-131
|
|
315224-26-1
|
|
Boc-Val-Ala-PAB-PNP
|
|
1884578-00-0
|
|
Ficlatuzumab
|
非拉妥组单抗
|
1174900-84-5
|
|
Vatelizumab
|
伐利组单抗
|
1238217-55-4
|
|
Futuximab
|
伏妥昔单抗
|
1310460-85-5
|
|
Andecaliximab
|
安德利昔单抗
|
1518996-49-0
|
|
Nemolizumab
|
奈莫利珠单抗
|
1476039-58-3
|
|
Satralizumab
|
萨特利珠单抗
|
1535963-91-7
|
|
Blontuvetmab
|
布隆妥维单抗
|
1608112-78-2
|
|
FTO-IN-3
|
|
2585198-87-2
|
|
BioE-1197
|
|
1268863-69-9
|
|
SR1664
|
|
1338259-05-4
|
|
Patritumab
|
帕曲妥单抗
|
1262787-83-6
|
|
Vesencumab
|
维森库单抗
|
1205533-60-3
|
|
Pateclizumab
|
帕替组单抗
|
1202526-59-7
|
|
Duligotuzumab
|
度戈妥珠单抗
|
1314238-96-4
|
|
Ligelizumab
|
利格利珠单抗
|
1322627-61-1
|
|
Evinacumab
|
依维苏单抗
|
1446419-85-7
|
|
Ensitrelvir fumarate
|
恩赛特韦富马酸盐
|
2757470-18-9
|
|
RY785
|
|
1393748-80-5
|
|
Urelumab
|
乌瑞芦单抗
|
934823-49-1
|
|
Erucin
|
三芥子酸甘油酯
|
4430-36-8
|
|
Radretumab
|
雷曲妥单抗
|
1253180-81-2
|
|
Inclacumab
|
|
1256258-86-2
|
|
Bezlotoxumab
|
贝洛托舒单抗
|
1246264-45-8
|
|
Dectrekumab
|
德屈库单抗
|
1528523-94-5
|
|
Ifabotuzumab
|
|
1234137-51-9
|
|
Mirvetuximab
|
米妥昔单抗
|
1453084-36-0
|
|
SCD1 inhibitor-3
|
|
1282606-48-7
|
|
2,4-Imidazolidinedione, 5-[3-[[4-[(3-methylphenyl)methoxy]phenyl]thio]-2-furanyl]-
|
|
877176-23-3
|
|
YM150
|
|
365462-23-3
|
|
Biotinyl Cystamine
|
生物素半胱胺
|
128915-82-2
|
|
Risankizumab
|
利散吉珠单抗
|
1612838-76-2
|
|
Solitomab
|
索利托单抗
|
1005198-65-1
|
|
Isatuximab
|
艾萨妥昔单抗
|
1461640-62-9
|
|
Cabiralizumab
|
卡比利珠单抗
|
1613144-80-1
|
|
Tamtuvetmab
|
坦妥维单抗
|
1608122-71-9
|
|
GSK251
|
|
2125968-05-8
|
|
YTX-465
|
|
2225824-53-1
|
|
(R)-GSK-3685032
|
|
2170140-50-6
|